scholarly journals Association of Alpha B-Crystallin Expression with Tumor Differentiation Grade in Colorectal Cancer Patients

Diagnostics ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 896
Author(s):  
Cristina Pagano ◽  
Giovanna Navarra ◽  
Patrizia Gazzerro ◽  
Mario Vitale ◽  
Maria Notarnicola ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Biomarker ◽  
Histological Grade ◽  
Small Heat Shock Protein ◽  
Immunohistochemical Analysis ◽  
Colonic Tissue ◽  
High Histological Grade ◽  
Colorectal Cancer Patients ◽  
The Relationship ◽  
Cryab Protein

Alpha B-crystallin (CRYAB, HSPB5) belongs to the small heat shock protein (HSP) family and is highly expressed in various human cancers, suggesting a crucial role in tumor progression. However, few studies have examined CRYAB expression in colorectal cancer (CRC). In the present study, we investigated the relationship between CRYAB expression and the clinicopathological features of CRC samples. We comparatively analyzed CRYAB protein expression in 111 CRC tissues and normal adjacent colonic tissue, observing that it was significantly lower in CRC tissues than in corresponding non-cancerous tissues. Moreover, immunohistochemical analysis showed a significant correlation between CRYAB expression and high histological grade G3 (p = 0.033). In summary, our results point to its possible application as a prognostic biomarker in CRC patients.

scholarly journals Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism

Oncotarget ◽  
2016 ◽  
Vol 7 (29) ◽  
pp. 46158-46172 ◽  
Author(s):  
Zhiliang Wei ◽  
Shougen Cao ◽  
Shanglong Liu ◽  
Zengwu Yao ◽  
Teng Sun ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Pilot Study ◽  
Gut Microbiota ◽  
Cancer Patients ◽  
Prognostic Biomarker ◽  
Colorectal Cancer Patients

scholarly journals Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients

2015 ◽  
Vol 2 (1) ◽  
Author(s):  
Qingsong Zhu ◽  
Evgeny Izumchenko ◽  
Alexander M Aliper ◽  
Evgeny Makarev ◽  
Keren Paz ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Prognostic Biomarker ◽  
Pathway Activation ◽  
Colorectal Cancer Patients

EGFR expression using immunohistochemistry (IHC) testing as a tool for selecting patients (pts) for treatment with cetuximab

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 13000-13000 ◽  
Author(s):  
A. L. Ervin-Haynes ◽  
R. M. Schinagl ◽  
M. R. Dalesandro ◽  
J. Roecker ◽  
H. Youssoufian ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trial ◽  
Routine Practice ◽  
Study Enrollment ◽  
Egfr Expression ◽  
Number Of Patients ◽  
The Us ◽  
Colorectal Cancer Patients ◽  
The Relationship ◽  
Cetuximab Therapy

13000 Background: EGFR expression, as determined by IHC, is currently used to select patients for cetuximab therapy. Based on prior studies in colorectal cancer patients, approximately 60 to 75% of patients express EGFR. There is increasing evidence that EGFR expression is not predictive of response to cetuximab therapy, and does not properly select patients who might benefit from such therapy (Chung et al 2005, Saltz et al 2005, Scartozi et al 2004, NCCN 2005). Such selection limits access to a considerable number of patients who might otherwise benefit. Methods: A clinical trial of cetuximab (Erbitux®) monotherapy is being conducted in 60 EGFR-undetectable patients with metastatic colorectal cancer at 14 sites in the US and Canada to explore the relationship between EGFR expression and cetuximab activity. Results: As of January 5, 2006, 112 patients have been screened. Of these patients, 33 (29%) were EGFR-undetectable and continued screening for study enrollment; 52 (46%) tested positive for EGFR expression; and 2 (2%) did not have enough tissue to evaluate EGFR status and were not enrolled onto the trial. The remaining 25 pts (22%), were initially found to be EGFR-undetectable by IHC testing at local labs, but were subsequently identified as EGFR-positive after reevaluation at a highly experienced, centralized laboratory. Conclusion: The majority of patients tested for EGFR expression are tested using the EGFR pharmDx™ IHC assay. Results of the IHC-based assay for EGFR expression are highly dependent upon sample preparation and the methods used in conducting the assay. Variability in methods among labs may result in poor identification of pts expressing EGFR. This finding, together with the growing evidence that EGFR expression is not predictive of response to cetuximab therapy, indicate that the current routine practice of tumor IHC EGFR testing for the purpose of selecting cetuximab therapy may be inappropriate and pts who could potentially benefit from cetuximab therapy are being excluded from a treatment option. [Table: see text]

MACC1 expression as a candidate prognostic biomarker in colorectal cancer patients receiving adjuvant oxaliplatin-based therapy.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 567-567 ◽  
Author(s):  
Lynn Katherine Symonds ◽  
Kelsey K. Baker ◽  
Mary Weber Redman ◽  
Lisa Koch ◽  
Kelly Carter ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cox Regression ◽  
Prognostic Biomarker ◽  
Patient Characteristics ◽  
Hazard Ratios ◽  
Platinum Based Chemotherapy ◽  
Tumor Mutational Burden ◽  
Colorectal Cancer Patients

567 Background: MACC1, part of the HGF-MET pathway, drives proliferation and regulation of MET expression in vitro. In vivo, MACC1 is associated with tumor progression and studies suggest greater MACC1 expression is associated with resistance to platinum-based chemotherapy. We hypothesized that MACC1 may be a prognostic biomarker in colorectal cancer (CRC). Methods: MACC1 expression was evaluated by immunohistochemistry on tumor microarrays (N = 428). Patients were stage I-III CRC who received an oxaliplatin-based regimen (either with 5-FU (FOLFOX) or capecitabine (XELOX)) within the HeCOG 6C/08 observational study. MACC1 expression was assessed by a blinded GI pathologist using a scale ranging from 0 (no staining) to 3+ (strong expression). Each patient had at least 3 samples and the strongest result was used for the final score. MACC1 positivity was defined as ≥2+ expression and 0-1+ as MACC1-. Cox regression models were used to estimate hazard ratios (HR) for the association of MACC1 expression with patient characteristics, disease-free (DFS), and overall survival (OS). Results: 400/428 CRC tumors were evaluable: 322 (80.5%) were MACC1+ and 78 (19.5%) MACC1-. Mucinous features were less likely in MACC1+ patients (24% vs. 38%, p = 0.02). Other unfavorable features including grade, lymphovascular invasion, perineural invasion, and tumor mutational burden were not significantly different. There was no difference for stage, microsatellite instability, BRAF, KRAS, or NRASstatus between MACC1+/- cancers. There was a trend towards worse survival in MACC1+ patients regardless of treatment (DFS HR 1.55 [95% CI: 0.87, 2.76], OS HR 1.59 [95% CI 0.74, 3.4]). This difference was not statistically significant for OS (p = 0.26) or DFS (p = 0.08) even when stratified by clinicopathologic variables. Conclusions: Patients with MACC1+ CRC tumors who received adjuvant oxaliplatin-based therapy were less likely to have mucinous histology. They had a trend toward independently worse survival that was not significant when accounting for stage and clinicopathologic variables. Studies focused on the predictive role of MACC1 and oxaliplatin in stage III CRC are in progress.

scholarly journals The Impact of KPNA2 on Prognosis of Colorectal Cancer Patients: A Meta-Analysis

2022 ◽  
Author(s):  
Zhangzhe Yan ◽  
Mingang He ◽  
Haoxin Shi ◽  
Haipeng Wang ◽  
Miao Qin ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Malignant Tumors ◽  
Hot Spot ◽  
Meta Analysis ◽  
Tumor Stage ◽  
Medical Database ◽  
High Level ◽  
Colorectal Cancer Patients ◽  
The Impact ◽  
The Relationship

Abstract Background and purpose: Colorectal cancer (CRC) is one of the most common malignant tumors with the highest mortality globally. At present, there is no exact biomarker to predict the prognosis and clinicopathological monitoring of CRC patients. Recent studies on the relationship of Karyopherin α 2 (KPNA2) expression and the prognosis of CRC has gradually become a hot spot while the results are still controversial. The aim of this study was to analyze and assess the prognostic role of KPNA2 in CRC patients. Methods: PubMed, Web of Science, Medline, EMBASE, CNKI, Wanfang, VIP, and Chinese Medical Database were systematically searched. The cohort study of high-level expression of KNPA2 and low-level expression of KPNA2 in CRC patients was included, the relevant data were extracted and the literature quality was evaluated. At the same time, the relationship between KPNA2 expression level and the overall survival (OS), the clinicopathological stage of CRC patients was studied. Meta-analysis was carried out by Stata MP 17.0 (Stata Corporation, College Station, TX, USA) software. Results: A total of 7 cohort studies involving 1166 patients were included. The analysis results showed that higher KPNA2 expression was significantly associated with higher tumor stage (OR=1.90, 95% CI 1.42–2.54), higher degree of tumor invasion (OR=2.14，95% CI 1.55-2.94), more lymph node metastasis (OR=2.20, 95% CI 1.68-2.88) and more distant metastasis (OR=3.66，95% CI 1.81-7.40). Moreover, higher KPNA2 expression was significantly associated with the shorter OS (HR=2.31, 95%CI 1.46-3.68).Conclusion: KPNA2 overexpression is an unfavorable prognostic factor for CRC patients. It could serve as a prognostic biomarker and as a potential therapeutic target for CRC.

Sign in / Sign up

Export Citation Format

Share Document